Neuropathology in mice expressing human α-synuclein

Journal of Neuroscience

Volumn 20, Issue 16, 2000, Pages 6021-6029

  Van Der Putten, Herman ^a   Wiederhold, Karl Heinz ^a   Probst, Alphonse ^b   Barbieri, Samuel ^a   Mistl, Claudia ^b   Danner, Simone ^a   Kauffmann, Sabine ^a   Hofele, Katja ^a   Spooren, Will P J M ^a   Ruegg, Markus A ^d   Lin, Shuo ^d   Caroni, Pico ^c   Sommer, Bernd ^a   Tolnay, Markus ^b   Bilbe, Graeme ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH   (Switzerland)

^d UNIVERSITY OF BASEL   (Switzerland)

Author keywords

A53T mutant; Dementia with Lewy bodies; Lewy pathology; Parkinson's disease; Transgenic mice; Ubiquitination; Wild type; Synuclein

Indexed keywords

ALPHA SYNUCLEIN; UBIQUITIN;

ALZHEIMER DISEASE; ANIMAL TISSUE; ARTICLE; DEMENTIA; DENERVATION; DOPAMINERGIC NERVE CELL; LEWY BODY; MOUSE; NERVE DEGENERATION; NEUROPATHOLOGY; NONHUMAN; PARKINSON DISEASE; PRESYNAPTIC INHIBITION; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 0034663176     PISSN: 02706474     EISSN: None     Source Type: Journal    
DOI: 10.1523/jneurosci.20-16-06021.2000     Document Type: Article

References (58)

1. Overexpression of the neuronal growth-associated protein GAP-43 induces nerve sprouting in the adult nervous system of transgenic mice
2. Argyrophilic glial inclusions in the midbrain of patients with Parkinson s disease and diffuse Lewy body disease are immunopositive for NACP/alpha-synuclein
3. Immunoelectron microscopic demonstration of NACP/α-synuclein-epitopes on the filamentous components of Lewy bodies in Parkinson's disease and in dementia with Lewy bodies
4. Aggregation of α-synuclein in Lewy bodies of sporadic Parkinson's disease and Dementia with Lewy bodies
5. Degradation of alpha-synuclein by proteasome
6. Silver staining method for demonstrating Lewy bodies in Parkinson's disease and argyrophilic oligodendrocytes in multiple system atrophy
7. Pattern of brain destruction in Parkinson's and Alzheimer's diseases
8. Extensive axonal Lewy neurites in Parkinson's disease: A novel pathological feature revealed by α-synuclein immunocytochemistry
9. Parkinson's disease: Affection of brain stem nuclei controlling premotor and motor neurons of the somatomotor system
10. Alzheimer's plaques and tangles: A controlled and enhanced silver staining method
11. Failure to find the alpha-synuclein gene missense mutation (G209A) in 100 patients with younger onset Parkinson's disease
12. Accelerated in vitro fibril formation by a mutant α-synuclein linked to early-onset Parkinson disease
13. Acceleration of oligomerization, not fibrillization, is a shared property of both α-synuclein mutations linked to early-onset Parkinson's disease: Implications for pathogenesis and therapy
14. Synthetic filaments assembled from C-terminally truncated α-synuclein
15. Relationships between Lewy bodies and pale bodies in Parkinson's disease
16. The distribution of Lewy bodies in the central and autonomic nervous systems in idiopathic paralysis agitans
17. Effects of the mutations Ala30 to Pro and Ala53 to Thr on the physical and morphological properties of alpha-synuclein protein implicated in Parkinson's disease
18. Low frequency of alpha-synuclein mutations in familial Parkinson's disease
19. A Drosophila model of Parkinson's disease
20. Neuropathology of Parkinson's disease
21. Ubiquitin-positive degenerating neurites in the brainstem in Parkinson's disease
22. Mutant and wild type human alpha-synucleins assemble into elongated filaments with distinct morphologies in vitro
23. A panel of epitope-specific antibodies detects protein domains distributed throughout human α-synuclein in Lewy bodies of Parkinson's disease
24. Filamentous nerve cell inclusions in neurodegenerative diseases
25. Clinical and neuropathological correlates of dementia with Lewy bodies
26. α-Synuclein immunoreactivity in dementia with Lewy bodies: Morphological staging and comparison with ubiquitin immunostaining
27. Silver staining of nerve axons in paraffin sections
28. Dementia with Lewy bodies. A distinct non-Alzheimer dementia syndrome
29. Nigral and cortical Lewy bodies and dystrophic nigral neurites in Parkinson's disease and cortical Lewy body disease contain α-synuclein immunoreactivity
30. Epitope mapping of LB509, a monoclonal antibody directed against human α-synuclein
31. Axonal transport of synucleins is mediated by all rate components
32. Physiology and pathophysiology of α-synuclein: Cell culture and transgenic animal models based on a Parkinson's disease-associated protein
33. Subcellular localization of wild-type and Parkinson's disease-associated mutant α-synuclein in human and transgenic mouse brain
34. MPTP induces alpha-synuclein aggregation in the substantia nigra of baboons
35. Ala30Pro mutation in the gene encoding α-synuclein in Parkinson's disease
36. The synuclein family
37. The ubiquitin pathway in Parkinson's disease
38. Immunocytochemical colocalization of the proteasome in ubiquitinated structures in neurodegenerative diseases and the elderly
39. Ubiquitin carboxyl-terminal hydrolase (PGP9.5) is selectively present in ubiquinated inclusion bodies characteristic of human degenerative disorders
40. An endogenous serine protease inhibitor alters epileptic activity and hippocampal long-term potentiation
41. Dopaminergic loss and inclusion body formation in α-synuclein mice: Implications for neurodegenerative disorders
42. α-Synuclein is present in Lewy bodies in sporadic Parkinson's disease
43. Both familial Parkinson's disease mutations accelerate alpha-synuclein aggregation
44. A new stain for quantitative measurement of sprouting at neuromuscular junctions
45. Pathology and biology of the Lewy body
46. Mutation in the α-synuclein gene identified in families with Parkinson's disease
47. Alphasynuclein immunoreactive Lewy bodies and Lewy neurites in Parkinson's disease are detectable by an advanced silver-staining technique
48. α-Synuclein in Lewy bodies
49. α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies
50. Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology
51. Abnormal accumulation of NACP/≃-synuclein in neurodegenerative disorders
52. Alpha-synuclein gene and Parkinson's disease
53. The alpha-synuclein Ala53Thr mutation is not a common cause of familial Parkinson's disease: A study of 230 European cases
54. Alpha-synuclein up-regulation in substantia nigra, dopaminergic neurons following administration of the parkinsonian toxin
55. NACP, a presynaptic protein, immunoreactivity in Lewy bodies in Parkinson's disease
56. Accumulation of α-synuclein/NACP is a cytopathological feature common to Lewy body disease and multiple system atrophy
57. Neuron-specific transgene expression in brain of mouse bcl-X(L) but not human bcl-2 gene reduces lesion size following permanent MCAO
58. Alpha-Synuclein fibrillogenesis is nucleation-dependent. Implications for the pathogenesis of Parkinson's disease